IRPSY yields 0.64% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 8
Combined, IRPSY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IRPSY + PFE for your $10,000?
IRPC Public Company Limited, together with its subsidiaries, provides petroleum and petrochemical products in Thailand, Singapore, and internationally. The company operates through Petroleum Products, Petrochemical Products, and Other Business segments. It offers petroleum products, including liquefied petroleum gas, gasohol, gasoline base, diesel, diesel base, gasoline, fuel oil, lube base oil, slack wax, aromatic extract, treated distillate aromatic extract and residue aromatic extract, asphalt, straight-run fuel oil, white spirit, C9 aromatic/aromatic, toluene, xylene, mixed xylenes; and polyethylene, polypropylene, acrylonitrile-butadiene-styrene, acrylonitrile styrene, polystyrene, expandable polystyrene, and additives. It also generates and distributes electricity, power, steam, industrial water, and air systems; and wastewater treatment services for industrial customers. In addition, the company offers port and tank services, such as tugboats, piloting services, lighters, fresh water and fuel, weigh scales, container yards, warehouses, and machines and equipment for the transshipment of goods. Further, it is involved in the provision of asset management and oil vessel renting services; manufacture and distribution of plastic resins; operation of vocational schools; distribution of non-woven fabric products and medical consumables; and distribution of petrochemical products, as well as power plant, jetty, and other utilities operations. The company was formerly known as Thai Petrochemical Industry Public Company Limited and changed its name to IRPC Public Company Limited in October 2006. IRPC Public Company Limited was incorporated in 1978 and is headquartered in Rayong, Thailand.
Full IRPSY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.